Advertisement


Jennifer K. Litton, MD, on Breast Cancer: EMBRACA Trial on Talazoparib vs Chemotherapy

AACR Virtual Annual Meeting 2020 I

Advertisement

Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, discusses study results of talazoparib vs chemotherapy in patients with BRCA1/2-mutated HER2-negative advanced breast cancer. In this final analysis, patient-reported outcomes continued to favor the PARP inhibitor, even though it did not improve overall survival compared with chemotherapy (Abstract CT071).



Related Videos

Breast Cancer
Immunotherapy

Steven J. O’Day, MD, on Triple-Negative Breast Cancer: Clinical Benefit With Pembrolizumab Plus Imprime PGG

Steven J. O’Day, MD, of the John Wayne Cancer Institute, discusses phase II results for the combination of pembrolizumab with a novel innate immune activator, Imprime PGG, as...

Lung Cancer

Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib

Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced ...

Solid Tumors

Nickolas Papadopoulos, PhD, on Liquid Biopsy to Screen for Multiple Cancer Types

Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women w...

Lung Cancer
Immunotherapy

Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy

Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pn...

Issues in Oncology

Kimlin T. Ashing, PhD, on Tobacco and Vape Shops in Neighborhoods With Lower-Income and Minority Populations

Kimlin T. Ashing, PhD, of City of Hope National Medical Center, discusses analyses that showed neighborhoods with lower-income and minority populations had a greater number o...

Advertisement

Advertisement



Advertisement